Corneal Collagen Cross-linking (CXL)
What is cross-linking?
Cross-linking is a medical procedure that combines the use of ultra-violet light and riboflavin eye drops.
What is the purpose of cross-linking?
The last two years have seen a marked increase in the prominence of corneal collagen cross-linking as a treatment strategy for progressive Keratoconus. This interest has arisen from a body of evidence documenting the biomechanical and cellular changes induced by cross-linking. The findings of this research provide a rationale for its use in Keratoconus to retard the progression of this common disease. A rapidly growing number of clinical reports suggest a consistent stabilizing effect of cross-linking along with a variable improvement in corneal shape and visual function in some patients. As a first-line treatment, the greatest aim of cross-linking is to reduce and stop Keratoconus in the early phase of the condition and to treat the progressive vision loss that occurs which can lead to corneal transplantation.
How does cross-linking work?
Riboflavin (vitamin B2) is dripped into the cornea and then exposed to ultra-violet light. The light causes the riboflavin to fluoresce, which leads to the formation of bonds between collagen molecules or simply stated, collagen cross-linking.
How effective is cross-linking?
The effects of cross-linking were maintained over the duration of follow-up with the progression of the disease documented in only two patients (who responded to re-treatment). Subsequent published reports from several other centers have described similar results. In 2008, Raiskup-Wolf et al. described which remains the largest published series comprising 241 eyes followed in Dresden for up to 6 years after cross-linking. This uncontrolled, retrospective study confirmed earlier findings with statistically significant improvements in astigmatism, best-corrected visual activity (BCVA) and maximum simulated keratometry values (Kmax) at 12 months. Flattening was observed in 54% of eyes with a mean change in Kmax of -1.91 D (P.
What is the safety profile regarding the use of ultra-violet light and of riboflavin in the eye?
The ultraviolet light exposure during a cross-linking procedure is comparable to, or even less than, the exposure of the eye to the ultraviolet light in sunlight for a full day outdoors in summer. The riboflavin drops are simply vitamin B2, commonly used in foods such as your breakfast cereal.
How long ago was the first one done?
The first human eyes were treated in 1998.
How safe is it in treating Keratoconus?
Very. The are no cuts in the body of the cornea. It is much safer than a corneal graft which has been very successful in the past and even than a gas permeable contact lens, and also there is no chance of rejection (some grafts tend to last around 10-15 years).
The transplant carries risks such as infection, rejection, cataracts, glaucoma, astigmatism, and failure. At 15 years, there is no difference in the survival rate between penetrating corneal transplants performed for Keratoconus and those performed for all other indications. Young Keratoconus patients are likely to need one or more repeated grafts during their lifetime. Crosslinking avoids the removal of any corneal structural tissue (only the surface epithelial cells are removed and these grow back mostly within 2 days).
Who is suitable and who is not?
With today’s improved technology, the vast majority of people suffering from Keratoconus and
Are there any age limits?
Not usually, but consult your ophthalmologist.
How is cross-linking performed?
Anesthetic eye drops are applied and the surface cells of the cornea (the epithelium) are gently removed so the riboflavin eye drops can penetrate into the cornea. The riboflavin eye drops are applied and allowed to soak into the cornea. The cornea is then irradiated with ultra-violet light. Advances in ultra-violet light sources have reduced total procedure time from one hour to as little as 12 minutes. At the completion of the procedure, a bandage contact lens is inserted and the eye is patched overnight.
Are there newer riboflavin formulations that do not require the epithelium to be removed?
Studies are ongoing with riboflavin formulations that that may allow the epithelium to remain intact during cross-linking. Check with your ophthalmologist regarding this option.
What are the possible complications and side effects of cross-linking?
Often transient and treatable and a part of the healing process: pain in the first 1-2 days, sensitivity to light for several days, haze within the cornea that may cause blurring for up to a few weeks. There are other, less common, possible complications, and side effects that your ophthalmologist can discuss with you.
Can cross-linking be combined with other treatments?
Cross-linking can be combined with Corneal Rings, Phakic Lens Implants, Refractive Lens Exchange, ARK, PRK, and LASEK.
Can cross-linking be redone if needed?
Yes, but during the past 13 years, a one-time treatment has been shown generally to be enough to treat progression.
Can I wear soft contact lenses after cross-linking?
One of the goals of cross-linking is to make the cornea more regular, allowing for soft contact lenses to replace the need for rigid gas permeable lenses. Rigid gas permeable lenses are good for vision in Keratoconus, but without warning can cause central scarring and/or can aggravate the condition. Your ophthalmologist will tell you if soft contact lenses are possible after cross-linking and how soon after treatment you may begin wearing them.
Are there any limitations or restrictions as to what I can do after cross-linking?
The blurring mentioned earlier may affect some people, especially in the first few days, and could limit work and driving during that time. However, consult your ophthalmologist.
Can anyone tell by my appearance that I have had cross-linking?
No. There is no change in the appearance of your eyes following cross-linking.
How many people have undergone a cross-linking procedure?
Tens-of-thousands of people have had their corneas cross-linked during the past 13 years. Due to the universal acceptance of the benefits of cross-linking among ophthalmologists, and recent advances in technology, the annual number of cross-linking procedures is expected to increase substantially.
Is cross-linking approved for general use in treating Keratoconus?
Cross-linking was fully approved for use in the EU in January 2007 and almost all other countries have now approved its general use to treat Keratoconus. Cross-linking began FDA clinical trials in the United States in 2008 and at least one company has completed those trials and is expected to submit its results during 2011.
Can both eyes be cross-linked at the same time?
Technically yes, but the short-term blurring due to the current procedure makes this impractical.
Will other eye treatments be a problem to perform after cross-linking?
No. It has no effect on any future surgery as far as been determined to date.
What other eye conditions can be treated with cross-linking?
Although most research to date has related to the treatment of Keratoconus, a role for CXL has also been suggested for other forms of corneal ectasia and a number of unrelated corneal conditions. Although cross-linking has been used in all these circumstances, other than for progressive Keratoconus, there is currently